Cargando…
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
BACKGROUND: Concerns for hyperkalaemia limit the use of mineralocorticoid receptor antagonists (MRAs). The frequency of MRA‐associated hyperkalaemia in real‐world settings and the extent of subsequent MRA discontinuation are poorly quantified. METHODS AND RESULTS: Observational study including all S...
Autores principales: | Trevisan, Marco, de Deco, Pietro, Xu, Hairong, Evans, Marie, Lindholm, Bengt, Bellocco, Rino, Barany, Peter, Jernberg, Tomas, Lund, Lars H., Carrero, Juan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607478/ https://www.ncbi.nlm.nih.gov/pubmed/29667759 http://dx.doi.org/10.1002/ejhf.1199 |
Ejemplares similares
-
Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
por: Löfman, Ida, et al.
Publicado: (2018) -
Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
por: Henrysson, Josefin, et al.
Publicado: (2022) -
Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project
por: Gasparini, Alessandro, et al.
Publicado: (2019) -
Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, Eberhard, et al.
Publicado: (2013) -
Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, E., et al.
Publicado: (2013)